What is ILC²?
Initiatives in Lung Cancer Care (ILC²) is an exciting Lung Ambition Alliance program that aims to support patient and caregiver non-profit organizations. It seeks to deliver initiatives that will improve the quality of care and close gaps in the patient experience of lung cancer care around the world. ILC² will fund innovative, promising, and proven projects around the world that can be supported and scaled to transform patient identification, quality of care, and patient outcomes.

What is the time window to apply?
Applications must be submitted online from November 1, 2019 to January 31, 2020.

Who is eligible to apply?
Registered charitable/not-for-profit organizations focused on lung cancer care are eligible. ILC² is not open to individuals.

What will be funded?
Funded projects must aim to improve the quality of care for lung cancer patients. They must be able to demonstrate measurable outcomes. Projects would need to commence within 6 months of an award being granted and be completed within 1 year (or 2 years for the projects requesting the highest funding).

How much funding can be applied for?
There are three categories of funding available, up to a maximum of $100,000 per application. The categories vary according to the size of the applicant organization, the project, and the intended scale and impact.

Where to apply?
More information is available at LungAmbitionAlliance.com. Please download the detailed Guidance Notes and determine if you are eligible and wish to apply. Application and correspondence must be in English.

ILC² grant applications will be reviewed and selected by the four founding partners of the Lung Ambition Alliance; the Global Lung Cancer Coalition, Guardant Health, the International Association for the Study of Lung Cancer and AstraZeneca. Funding for the ILC² grant is provided by AstraZeneca.